본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

망막정맥폐쇄와 당뇨망막병증에서 황반부종 치료를 위한 유리체내 베바시주맙 주입술의 효과

이용수 2

영문명
Long-Term Results of Intravitreal Bevacizumab Injection for Macular Edema : Retinal Vein Obstruction and Diabetic Retinopathy
발행기관
대한안과학회
저자명
이승원 김무상 김응석 곽형우 유승영,Seung Won Lee, MD, Moo Sang Kim, MD, Eung Suk Kim, MD, Hyung Woo Kwak, MD, Seung Young Yu, MD
간행물 정보
『대한안과학회지』Ophthalmological Society,volume50,number2, 211~218쪽, 전체 8쪽
주제분류
의약학 > 기타의약학
파일형태
PDF
발행일자
2009.02.15
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Purpose: To evaluate the long-term results of intravitreal bevacizumab injection for macular edema (ME) due to retinal vein obstruction (RVO) and diabetic retinopathy (DR). Methods: The objects of study were patients with decreased visual acuity due to ME with RVO and DR for whom intravitreal injections of 1.25 mg (0.05 ml) bevacizumab were repeated three times with an interval of six weeks and who were available for a follow-up period of more than 12 months. The patients underwent additional bevacizumab injections if ME increased as assessed by optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline and follow-up visits. Results: There were 16 patients with RVO and 18 patients with DR. In the RVO group, the mean length of follow-up was 12.4±1.1 months, the mean baseline BCVA was 0.75±0.32 and the final BCVA was 0.42±0.25, a difference that was statistically significant (p<0.05). The mean CMT at baseline was 588.5±301.0 μm and this decreased to a mean of 191.8±112.0 μm at the end of the follow-up period (p<0.05). In the DR group, the mean length of follow-up was 15.4±3.2 months, the mean baseline BCVA was 0.63±0.33 and the final BCVA was 0.61±0.37, a difference that was not statistically significant (p>0.05). The mean CMT at baseline was 462.0±195.0 μm and decreased to a mean of 282.2±177.3 μm at the end of the follow-up period (p<0.05). Conclusions: In RVO and DR, three injections of intravitreal bevacizumab with an interval of six weeks and additional injections as indicated were effective in reducing ME and showed especially good results in improvement of visual acuity for ME due to RVO.

목차

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

이승원,김무상,김응석,곽형우,유승영,Seung Won Lee, MD, Moo Sang Kim, MD, Eung Suk Kim, MD, Hyung Woo Kwak, MD, Seung Young Yu, MD. (2009).망막정맥폐쇄와 당뇨망막병증에서 황반부종 치료를 위한 유리체내 베바시주맙 주입술의 효과. 대한안과학회지, 50 (2), 211-218

MLA

이승원,김무상,김응석,곽형우,유승영,Seung Won Lee, MD, Moo Sang Kim, MD, Eung Suk Kim, MD, Hyung Woo Kwak, MD, Seung Young Yu, MD. "망막정맥폐쇄와 당뇨망막병증에서 황반부종 치료를 위한 유리체내 베바시주맙 주입술의 효과." 대한안과학회지, 50.2(2009): 211-218

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제